The risk of cancer in users of statins

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2388-2394

  Graaf, Matthijs R ^a   Beiderbeck, Annette B ^a   Egberts, Antoine C G ^a   Richel, Dick J ^a   Guchelaar, Henk Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SEX HORMONE; CARDIOVASCULAR AGENT; ENZYME INHIBITOR;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; FOLLOW UP; GEOGRAPHY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; AGED; CASE CONTROL STUDY; COMPARATIVE STUDY; MALE; MIDDLE AGED; NEOPLASM; RISK; TIME;

AGED; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASMS; RISK; TIME FACTORS;

EID: 2942754163     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.027     Document Type: Article

References (34)

1. Pedersen TR, Wilhelmsen L, Faergeman O, et al: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86:257-262, 2000
2. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995
3. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279:1615-1622, 1998
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357, 1998
5. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
6. College voor zorgverzekeringen: Lipidenverlagende middelen 1995-1999. GIPeilingen 16:44-46, 2001
7. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
8. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
9. Rubins JB, Greatens T, Kratzke RA, et al: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157:1616-1622, 1998
10. Maksumova L, Ohnishi K, Muratkhodjaev F, et al: Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 14:1444-1450, 2000
11. Sumi S, Beauchamp RD, Townsend CM Jr, et al: Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103:982-989, 1992
12. Kawata S, Nagase T, Yamasaki E, et al: Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 69:1015-1020, 1994
13. Macaulay RJ, Wang W, Dimitroulakos J, et al: Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 42:1-11, 1999
14. Dimitroulakos J, Nohynek D, Backway KL, et al: Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93:1308-1318, 1999
15. Dimitroulakos J, Ye LY, Benzaquen M, et al: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7:158-167, 2001
16. Alonso DF, Farina HG, Skilton G, et al: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83-93, 1998
17. Iishi H, Tatsuta M, Baba M, et al: rasp21 Isoprenylation inhibition induces flat colon tumors in Wistar rats. Dis Colon Rectum 43:70-75, 2000
18. Thibault A, Samid D, Tompkins AC, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491, 1996
19. Kawata S, Yamasaki E, Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: A randomized controlled trial. Br J Cancer 84:886-891, 2001
20. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996
21. Bjerre L, Lelorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110:716-723, 2001
22. Blais L, Desgagné A, Lelorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med 160:2363-2368, 2000
23. Goldstein M: Reductase inhibitors and the risk of cancer. Arch Intern Med 161:1460, 2001
24. Lau HS, de Boer A, Beuning KS, et al: Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619-625, 1997
25. Herings R: Pharmo, A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands [thesis in pharmaco-epidemiology and pharmacotherapy]. The Netherlands, Utrecht University, 1993, pp 17-32
26. Von Korff M, Wagner E, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203, 1992
27. Visser O, Coebergh JWW, van Dijck JAAM, et al: Incidence of cancer in the Netherlands 1998. Utrecht, 2002. http://www.ikc.nl/vvik/kankerregistratie/ img_kr_cijfersaug02/divers/VIKC-Incidence.pdf
28. Simons M, Keller P, Dichgans J, et al: Cholesterol and Alzheimer's disease: Is there a link? Neurology 57:1089-1093, 2001
29. Jick H, Zomberg GL, Jick SS, et al: Statins and the risk of dementia. Lancet 356:1627-1631, 2000
30. Wolozin B, Kellman W, Ruosseau P, et al: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443, 2000
31. Coons JC: Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 36:326-330, 2002
32. Adjei A: Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074, 2001
33. Negre-Aminou P, van Vliet AK, van Erck M, et al: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types. Biochim Biochim Biophys Acta 1345:259-268, 1997
34. Wang W, Macaulay RJ: Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer 82:430-434, 1999